Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

XERS - Xeris Biopharma Holdings, Inc.


IEX Last Trade
2.9
0   0%

Share volume: 304,478
Last Updated: Tue 24 Dec 2024 04:30:32 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.51%

PREVIOUS CLOSE
CHG
CHG%

$2.90
0.53
0.15%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
30%
Profitability 15%
Dept financing 25%
Liquidity 75%
Performance 35%
Company vs Stock growth
vs
Performance
5 Days
7.38%
1 Month
13.31%
3 Months
26.45%
6 Months
65.40%
1 Year
66.99%
2 Year
176.98%
Key data
Stock price
$2.90
P/E Ratio 
-7.03
DAY RANGE
$3.41 - $3.51
EPS 
-$0.42
52 WEEK RANGE
$1.75 - $3.87
52 WEEK CHANGE
$66.99
MARKET CAP 
418.687 M
YIELD 
N/A
SHARES OUTSTANDING 
148.999 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.76
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,702,287
AVERAGE 30 VOLUME 
$1,787,731
Company detail
CEO: Paul R. Edick
Region: US
Website: xerispharma.com
Employees: 290
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Xeris Biopharma Holdings, Inc. engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, a therapy for the. treatment of hyperkalemic, hypokalemic. and related variants of primary periodic paralysis.

Recent news